Gritstone Bio ROA 2017-2024 | GRTSQ
Current and historical return on assets (ROA) values for Gritstone Bio (GRTSQ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Gritstone Bio ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-06-30 |
$-0.13B |
$0.14B |
-81.86% |
| 2024-03-31 |
$-0.14B |
$0.14B |
-79.45% |
| 2023-12-31 |
$-0.14B |
$0.18B |
-69.17% |
| 2023-09-30 |
$-0.14B |
$0.19B |
-64.11% |
| 2023-06-30 |
$-0.13B |
$0.22B |
-59.16% |
| 2023-03-31 |
$-0.13B |
$0.21B |
-57.47% |
| 2022-12-31 |
$-0.12B |
$0.24B |
-53.16% |
| 2022-09-30 |
$-0.12B |
$0.21B |
-50.64% |
| 2022-06-30 |
$-0.12B |
$0.21B |
-46.52% |
| 2022-03-31 |
$-0.11B |
$0.24B |
-44.09% |
| 2021-12-31 |
$-0.08B |
$0.28B |
-29.41% |
| 2021-09-30 |
$-0.07B |
$0.27B |
-29.88% |
| 2021-06-30 |
$-0.07B |
$0.22B |
-34.31% |
| 2021-03-31 |
$-0.07B |
$0.25B |
-38.48% |
| 2020-12-31 |
$-0.11B |
$0.22B |
-64.22% |
| 2020-09-30 |
$-0.11B |
$0.12B |
-68.83% |
| 2020-06-30 |
$-0.11B |
$0.15B |
-61.54% |
| 2020-03-31 |
$-0.10B |
$0.16B |
-52.55% |
| 2019-12-31 |
$-0.10B |
$0.18B |
-47.74% |
| 2019-09-30 |
$-0.08B |
$0.21B |
-41.90% |
| 2019-06-30 |
$-0.08B |
$0.23B |
-42.49% |
| 2019-03-31 |
$-0.07B |
$0.18B |
-57.74% |
| 2018-12-31 |
$-0.06B |
$0.19B |
-84.49% |
| 2018-06-30 |
$-0.04B |
$0.00B |
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
